Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum, metformini hydrochloridum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, metformini hydrochloridum 500 mg, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.03 mg. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum, metformini hydrochloridum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, metformini hydrochloridum 850 mg, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: lactosum monohydricum 13.7 mg, hypromellosum, e 171, triacetinum, e 172 (rubrum), pro compresso obducto corresp. natrium 1.74 mg. - il diabete mellito di tipo 2 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - sitagliptinum, metformini hydrochloridum - compresse rivestite con film - sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, metformini hydrochloridum 1000 mg, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 2.02 mg. - il diabete mellito di tipo 2 - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

as grindeks - metformina e sitagliptina - metformina e sitagliptina

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 500 mg, sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 50 mg, povidonum k 30, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, triethylis citras, e 171, talcum, e 172 (rubrum), pro compresso obducto corresp. natrium 1.84 mg. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 850 mg, sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 50 mg, povidonum k 30, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, triethylis citras, e 171, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 2.99 mg. - farmaco antidiabetico orale - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - metformini hydrochloridum, sitagliptinum - compresse rivestite con film - metformini hydrochloridum 1000 mg, sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 50 mg, povidonum k 30, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, triethylis citras, e 171, talcum, e 172 (rubrum), e 172 (flavum), pro compresso obducto corresp. natrium 3.5 mg. - farmaco antidiabetico orale - synthetika